The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

OBJECTIVE: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. METHODS: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., Whitham, Ruth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Contemporary Issues
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451044/
https://www.ncbi.nlm.nih.gov/pubmed/25911108
http://dx.doi.org/10.1212/WNL.0000000000001608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451044/
https://www.ncbi.nlm.nih.gov/pubmed/25911108
http://dx.doi.org/10.1212/WNL.0000000000001608

Ejemplares similares